Compare MSGM & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | IMNN |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.9M |
| IPO Year | 2021 | 1985 |
| Metric | MSGM | IMNN |
|---|---|---|
| Price | $3.07 | $3.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | 68.4K | ★ 75.0K |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $9,424,138.00 | N/A |
| Revenue This Year | $69.07 | N/A |
| Revenue Next Year | $30.56 | N/A |
| P/E Ratio | $3.82 | ★ N/A |
| Revenue Growth | ★ 11.38 | N/A |
| 52 Week Low | $0.73 | $2.99 |
| 52 Week High | $5.41 | $41.22 |
| Indicator | MSGM | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 50.15 |
| Support Level | $2.93 | $2.99 |
| Resistance Level | $3.25 | $4.20 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 42.42 | 72.73 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).